Tempus signs expanded strategic agreements with astrazeneca and pathos to develop the largest multimodal foundation model in oncology

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced multi-year, strategic collaborations with astrazeneca (lse/sto/nasdaq: azn) and pathos ai, inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology.
TEM Ratings Summary
TEM Quant Ranking